Is American Chemical Society Legit?

The American Chemical Society (ACS) demonstrates a generally stable financial position with consistent revenue streams over the past decade, averaging around $150,000 annually. While there have been fluctuations in expenses, such as a significant surplus in 2021 ($250,733 revenue vs. $52,613 expenses) and a deficit in 2022 ($116,435 revenue vs. $141,646 expenses), the organization has consistently maintained zero liabilities across all reported periods, indicating strong financial management and a lack of debt. Their asset base has shown substantial growth, increasing from $532,839 in 2014 to $1,174,570 in 2023, suggesting effective asset accumulation and preservation. The consistent reporting of 0% officer compensation across all filings indicates a high degree of transparency regarding executive pay, or that officers are not compensated, which is a positive sign for donor confidence. Spending efficiency appears to vary year-to-year, with some periods showing expenses exceeding revenue (e.g., 2022, 2018, 2017) and others demonstrating significant surpluses (e.g., 2021, 2020). However, the overall trend of increasing assets despite these fluctuations suggests that the organization is capable of managing its resources effectively over the long term. The absence of liabilities is a particularly strong indicator of financial health and responsible fiscal practices. The consistent filing of IRS Form 990s over 13 periods further underscores their commitment to transparency and regulatory compliance. Given the available data, ACS appears to be a financially sound organization with a strong balance sheet and a clear commitment to transparency, particularly concerning executive compensation. While a detailed breakdown of program, administrative, and fundraising expenses is not provided in the summary data, the consistent growth in assets and absence of liabilities are positive indicators of overall financial health and responsible stewardship of resources.